Research
Hormonal
The share of prescriptions for semaglutide (Wegovy) increased to 27.7% among advanced practice practitioners (APPs) by February 2024.
Practitioners should consider the growing preference for semaglutide in obesity treatment.
StrongSupportsmedium confidence
Wegovy's share of total OMDs increased to 27.7% and 28.3% (both February 2024) among APPs and PCPs and internists, respectively.
Why this rating
Based on the analysis of prescription data.
Source
Longitudinal Analysis of Obesity Drug Use and Public Awareness
Philipp Berning et al. · JAMA Network Open · 2025
cross-sectionalCited 57×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →